NCT07624305ClinicalTrials.gov
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)
En bref
The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered…
Phase 32 800 participants recherchés478 sites27 pays
Catégories
Enregistré dans 1 registre
- ClinicalTrials.govNCT07624305Ouvrir cette fiche sur ClinicalTrials.govSynchronisé il y a 2 mois
Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.
Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.
Cette étude vous intéresse ?
Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-06-03; recorded start 2026-09-01
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
- Multi-centre8/8
Multi-centre: 45 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 2,800 participants (target), run at 478 sites, across 27 countries.
How this score is built
- Enrolment34/40
2,800 participants (target)
- Site count19/25
45 sites
- Country count12/15
8 countries
- Planned duration9/10
Planned over about 47 months
- Sponsor scale10/10
AstraZeneca has led 999 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Résumé
The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from interventional trials.
Affections
- Renal Insufficiency, Chronic
Éligibilité
| Sexe | Tous |
|---|---|
| Âges | 18 Years – 99 Years |
| Volontaires sains | Non |
Éligibilité telle qu'elle figure dans le registre
Éligibilité en énoncés simples
Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.
Conception de l'étude
| Type d'étude | Interventionnelle |
|---|---|
| Phase | Phase 3 |
| Répartition | Randomisée |
| Modèle d'intervention | PARALLEL |
| Objectif principal | TREATMENT |
| Insu | QUADRUPLE (4) |
| Recrutement | 2 800 participants recherchés |
Promoteur et collaborateurs
- AstraZeneca Promoteur
Groupes et interventions
- Balcinrenone/dapagliflozinEXPERIMENTAL
Patient receives once daily 1 capsule balcinrenone 15 mg and dapagliflozin 10 mg and 1 placebo tablet matching dapagliflozin.
- DapagliflozinACTIVE_COMPARATOR
Patient receives once daily 1 placebo capsule matching balcinrenone and dapagliflozin and 1 tablet dapagliflozin 10 mg.
Interventions
- Médicament Balcinrenone/dapagliflozin
balcinrenone/dapagliflozin 15 mg/10 mg
- Médicament Dapagliflozin
dapagliflozin 10 mg
- Médicament Placebo matching Dapagliflozin
matching placebo for dapagliflozin 10 mg
- Médicament Placebo matching balcinrenone/dapagliflozin
matching placebo for balcinrenone/dapagliflozin
Critères de jugement
Critère de jugement principal
Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure, sustained 50% or greater decline in eGFR, and heart failure event
Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure * Initiation of maintenance dialysis or * Kidney transplantation * Sustained ≥ 50% decline from baseline in eGFR * HF with or without hospitalisation
Délai Up to 46 months.
Critère de jugement secondaire
Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure and sustained 50% or greater decline in eGFR.
Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure: * Initiation of maintenance dialysis or * Kidney transplantation Sustained ≥ 50% decline from baseline in eGFR
Délai Up to 46 months.
Critère de jugement secondaire
Change in urinary albumin to creatinine ratio to Week 24
Change from baseline to Week 24 in urinary albumin to creatinine ratio
Délai Baseline to Week 24
Critère de jugement secondaire
Time to first occurrence of cardiovascular death or heart failure event.
Time from randomization to first occurrence of any of the components of the composite: * CV death * HF with or without hospitalisation
Délai Up to 46 months.
Critère de jugement secondaire
Time to cardiovascular death
Time from randomization to cardiovascular death.
Délai Up to 46 months.
Critère de jugement secondaire
Time to death from any cause
Time from randomization to death from any cause.
Délai Up to 46 months.
Dates
| Date de début | 1 septembre 2026 (réelle) |
|---|---|
| Achèvement principal | 1 juillet 2030 (estimée) |
| Achèvement | 1 juillet 2030 (estimée) |
| Première publication | 3 juin 2026 (réelle) |
| Dernière mise à jour | 24 septembre 2026 |
| Résultats publiés | Non précisé dans la fiche du registre |
| Statut vérifié pour la dernière fois | septembre 2026 |
Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.
Lieux
33 sites sont en recrutement
Argentina
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Research Site | CABA | Pas encore en recrutement | |
| Research Site | Capital Federal | Pas encore en recrutement | |
| Research Site | Ciudad de Buenos Aires | Pas encore en recrutement | |
| Research Site | La Plata | Pas encore en recrutement | |
| Research Site | Lanús Este | Pas encore en recrutement | |
| Research Site | Mar del Plata | Pas encore en recrutement | |
| Research Site | Rosario | Pas encore en recrutement | |
| Research Site | Rosario | Pas encore en recrutement | |
| Research Site | Rosario | Pas encore en recrutement | |
| Research Site | San Nicolás | Pas encore en recrutement | |
| Research Site | Santa Fe | Pas encore en recrutement | |
| Research Site | Santa Fe | Pas encore en recrutement |
Austria
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Research Site | Feldkirch | Pas encore en recrutement | |
| Research Site | Innsbruck | Pas encore en recrutement | |
| Research Site | Linz | Pas encore en recrutement | |
| Research Site | Sankt Pölten | Pas encore en recrutement | |
| Research Site | Vienna | Pas encore en recrutement | |
| Research Site | Vienna | Pas encore en recrutement | |
| Research Site | Vienna | Pas encore en recrutement | |
| Research Site | Vienna | Pas encore en recrutement | |
| Research Site | Wels | Pas encore en recrutement | |
| Research Site | Wiener Neustadt | Pas encore en recrutement |
Brazil
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Research Site | Barretos | Pas encore en recrutement | |
| Research Site | Belo Horizonte | Pas encore en recrutement | |
| Research Site | Belo Horizonte | Pas encore en recrutement | |
| Research Site | Belém | Pas encore en recrutement | |
| Research Site | Campinas | Pas encore en recrutement | |
| Research Site | Goiânia | Pas encore en recrutement | |
| Research Site | Natal | Pas encore en recrutement | |
| Research Site | Recife | Pas encore en recrutement | |
| Research Site | São Caetano do Sul | Pas encore en recrutement | |
| Research Site | São José do Rio Preto | Pas encore en recrutement | |
| Research Site | São José dos Campos | Pas encore en recrutement | |
| Research Site | São Paulo | Pas encore en recrutement | |
| Research Site | São Paulo | Pas encore en recrutement | |
| Research Site | São Paulo | Pas encore en recrutement | |
| Research Site | São Paulo | Pas encore en recrutement |
Bulgaria
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Research Site | Blagoevgrad | Pas encore en recrutement | |
| Research Site | Nova Zagora | Pas encore en recrutement | |
| Research Site | Pleven | Pas encore en recrutement | |
| Research Site | Plovdiv | Pas encore en recrutement | |
| Research Site | Sandanski | Pas encore en recrutement | |
| Research Site | Sevlievo | Pas encore en recrutement | |
| Research Site | Sofia | Pas encore en recrutement | |
| Research Site | Sofia | Pas encore en recrutement | |
| Research Site | Sofia | Pas encore en recrutement | |
| Research Site | Stara Zagora | Pas encore en recrutement | |
| Research Site | Varna | Pas encore en recrutement |
Canada
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Research Site | Brampton | Ontario | Pas encore en recrutement |
| Research Site | Calgary | Alberta | Retiré |
428 sites supplémentaires sont indiqués dans la fiche du registre.
Documents de l'étude
Aucun document n'est lié dans cette fiche du registre.
Évolution au fil du temps
- 24 septembre 2026
Statut modifié
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 24 septembre 2026
Recrutement ouvert
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- 24 septembre 2026
Site ajouté
433 sites added (478 total)
45478